Gilead Sciences (NQ:GILD)

144.74 -2.76 (-1.87%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

78 79 Next >

Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition ↗

March 24, 2026

Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.

Via Benzinga

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...

Via MarketMinute

GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors ↗

March 10, 2026

Via Chartmill

3 Reasons to Avoid GILD and 1 Stock to Buy Instead

March 18, 2026

Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead ...

Via StockStory

Topics Stocks

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Movers and shakers in today's after-hours session for S&P500 stocks? ↗

March 16, 2026

Via Chartmill

2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

March 16, 2026

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

Via Barchart.com

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

March 11, 2026

Via Benzinga

2 Recession-Resistant Dividend Stocks to Buy Now ↗

March 11, 2026

It's important to always be prepared.

Via The Motley Fool

Topics Economy

What 16 Analyst Ratings Have To Say About Gilead Sciences ↗

March 10, 2026

Via Benzinga

3 Blue-Chip Stocks Built for a Rotating Market ↗

March 08, 2026

Via MarketBeat

These 3 Cash Flow Machines Provide Stability in Uncertain Markets ↗

March 06, 2026

Via MarketBeat

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

March 02, 2026

From Gilead Sciences, Inc.

Via Business Wire

Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

P/E Ratio Insights for Gilead Sciences ↗

February 27, 2026

Via Benzinga

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 27, 2026

Via Chartmill

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

February 27, 2026

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

Via Barchart.com

Topics ETFs

Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Kymera (KYMR) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results

February 26, 2026

Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir...

Via MarketMinute

Topics Intellectual Property

Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Arcus (RCUS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

February 25, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗

February 25, 2026

Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash.

Via Benzinga

Is Amgen Stock Outperforming the Dow?

February 25, 2026

Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.